Opaleye Management »

Nextcure shares owned by Opaleye Management

Quarter-by-quarter ownership of Nextcure (NXTC) shares owned by Opaleye Management from 13F filings

Historical chart of Opaleye Management investment in Nextcure

Tip: Access up to 7 years of quarterly data

All positions including Nextcure held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nextcure by Opaleye Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.5M 141k 10.68

More positions owned by Opaleye Management

Harrow Health (HROW)
Liquidia Corporation Com New (LQDA)
Eton Pharmaceuticals (ETON)
Sol-gel Technologies Shs New (SLGL)
Rhythm Pharmaceuticals (RYTM)
Apogee Therapeutics (APGE)
Disc Medicine (IRON)
Urogen Pharma (URGN)
Crescent Biopharma (CBIO)
Stoke Therapeutics (STOK)
Perspective Therapeutics Com New (CATX)
Rezolute Com New (RZLT)
Meiragtx Holdings (MGTX)
Tg Therapeutics (TGTX)
Sanuwave Health (SNWV)

View all positions for Opaleye Management

Top funds holding Nextcure

Squadron Capital Management
Affinity Asset Advisors
Ikarian Capital
Sofinnova Ventures
Silverarc Capital Management
Exome Asset Management
Pfizer
Opaleye Management
AWM Investment Company
Vanguard Group
Boothbay Fund Management
Renaissance Technologies
Geode Capital Management
BlackRock
Woodline Partners

View all funds holding Nextcure